Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.

In our retrospective analysis, SABR was associated with favorable levels of PFS and OS in patients with oligometastases. The limitations of our study were lacking high-level evidence, and randomized studies to compare SABR and palliative standard of care are mandatory.